- Comparative efficacy of first-line natalizumab vs IFN-Beta or glatiramer acetate in relapsing MS2016 | First Faculty of Medicine
- Expression of IP-10, CXCR3 and IFN-beta in affected and non-affected tissues of patients with polymyositis and dermatomyositisPublication without faculty affiliation
- Monocyte NOTCH2 expression predicts IFN-beta immunogenicity in multiple sclerosis patients2018 | First Faculty of Medicine
- MxA mRNA decrease preceding NAb detection in IFN beta-treated MS patients2017 | First Faculty of Medicine, Second Faculty of Medicine
- Myxovirus Resistance Protein A mRNA Expression Kinetics in Multiple Sclerosis Patients Treated with IFN beta2017 | First Faculty of Medicine, Second Faculty of Medicine
- Monitoring of interferon beta bioactivity in the multiple sclerosis2011 | Second Faculty of Medicine
- Using Serum Metabolomics to Predict Development of Anti-drug Antibodies in Multiple Sclerosis Patients Treated With IFN beta2020 | First Faculty of Medicine
- The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL2009 | First Faculty of Medicine
- Options for changing therapy for persistent flu-like syndrome during treatment with interferon-Beta in patients with multiple sclerosis2012 | Publication without faculty affiliation
- Abrogation of IFN-gamma Signaling May not Worsen Sensitivity to PD-1/PD-L1 Blockade2020 | Faculty of Science
- Alemtuzumab long-term immunologic effect Treg suppressor function increases up to 24 months2016 | First Faculty of Medicine
- Monitoring of the Biological Effect of Interferon Beta in the Treatment of Multiple Sclerosis2013 | Second Faculty of Medicine
- Myxovirus resistance protein A in interferon-β therapy in patients with multiple sclerosis and treatment effectiveness monitoring algorithm2016 | First Faculty of Medicine, Second Faculty of Medicine
- Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study2019 | First Faculty of Medicine
- Interferon-beta or azathioprine as add-on therapies in patients with active multiple sclerosis2012 | First Faculty of Medicine
- Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis2009 | Publication without faculty affiliation
- Early predictors of non-response to interferon in multiple sclerosis2012 | First Faculty of Medicine
- Fingolimod in Real Clinical Practice2017 | First Faculty of Medicine
- Immune sensing of mouse polyomavirus DNA by p204 and cGAS DNA sensors2021 | Faculty of Science
- Monitoring of radiologic disease activity by serum neurofilaments in MS2020 | First Faculty of Medicine
- A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis2014 | First Faculty of Medicine